Q-omics provides the consensus-scored MIR663B profile across patient tissues and cancer cell-line models. MIR663B expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, MIR663B is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, MIR663B RNA expression shows 5,221 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, and STAD as cancer lineages where MIR663B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR663B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR663B survival associations across molecular data types. MIR663B RNA expression shows survival associations in the most cancer types (10), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR663B RNA expression–survival associations across cancer types. High MIR663B expression shows unfavorable associations in LIHC, LUSC, LGG, TGCT and LUAD, but favorable associations in STAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for MIR663B RNA expression.
This table summarizes MIR663B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR663B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR663B shows lower tumor expression in STAD. The STAD box plot shows higher MIR663B RNA expression in normal versus tumor tissue (log2 FC = −0.660, t-test p = .042).
This table shows molecular features associated with MIR663B in patient tissues and cancer cell lines. In patient samples, MIR663B shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
